Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Macrogol 3350 + sodium chloride + sodium bicarbonate + potassium chloride is an osmotic laxative combination medication used for bowel cleansing prior to colonoscopy and for the treatment of constipation and fecal impaction. The primary active ingredient, macrogol 3350 (polyethylene glycol 3350), is a high-molecular-weight polymer that acts as an osmotic agent, drawing water into the intestinal lumen to soften stool and increase bowel motility. The inclusion of electrolytes (sodium chloride, sodium bicarbonate, and potassium chloride) is intended to maintain isotonicity and prevent clinically significant changes in electrolyte balance or hydration status during the cleansing process. This formulation is supplied as a powder for reconstitution and is approved for use in both adults and pediatric patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on macrogol 3350 + sodium chloride + sodium bicarbonate + potassium chloride.